These findings, together with our data showing that G3BP1-depleted fibroblasts are still able to enter senescence, demonstrate that G3BP1 constitutes an alternative target to design a new generation of anti-cancer drugs able to prevent SASP production without affecting the senescence phenotype and its benefits. This evidence concerns the gene G3BP1 and cancer.